J Cosmet Med 2019; 3(2): 125-129  https://doi.org/10.25056/JCM.2019.3.2.125
Improvement of rosacea by injection of platelet-rich plasma
Uekyoung Hwang, MD, MPh
Yeline Clinic, Seongnam, Rep. of Korea
Uekyoung Hwang
E-mail: yjukhome@daum.net
Received: December 4, 2019; Revised: December 23, 2019; Accepted: December 28, 2019; Published online: December 31, 2019.
© Korean Society of Korean Cosmetic Surgery. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Rosacea is a chronic facial inflammatory disease characterized by erythema, papules, telangiectasia, and recurrent flushing. Many studies have documented the crucial role that an immature immune system plays in the progression of rosacea. Various studies have illustrated the potential effectiveness of platelet-rich plasma (PRP) on the inhibition of inflammation. Although rosacea is a disease caused by inflammation accompanied by an immature immune system, there is no research explaining the effects of PRP on rosacea through the regulation of immunity and inflammation. The PRP was prepared using the SmartPReP®2 APC+TM in three participants who provided informed consent. The centrifuged PRP (total 4-5 ml) was then injected into the facial dermal area using a 26-gauge 5-cm cannula. In all three cases, the erythema in the cheek and chin area was severe, and telangiectasia was seen in the cheek preoperatively. Postoperatively, erythema and telangiectasia improved significantly during weeks 4 and 12. We believe this is the first article to document the potential therapeutic effects of PRP enriched with CD34+ stem cells in the peripheral blood for the treatment of rosacea. In conclusion, PRP enriched with CD34+ stem cells in the peripheral blood may have a potential additive therapeutic effect on rosacea via an immunomodulation effect. Long-term prospective follow-up studies are warranted to confirm the beneficial effect of PRP enriched with CD34+ stem cells in the peripheral blood for the treatment of rosacea.
Keywords: CD34; dermatitis; platelet-rich plasma; rosacea
  1. Li Y, Xie H, Deng Z, Wang B, Tang Y, Zhao Z, et al. Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis. Int Immunopharmacol 2019;67:326-34.
    Pubmed CrossRef
  2. Two AM, Hata TR, Nakatsuji T, Coda AB, Kotol PF, Wu W, et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. J Invest Dermatol 2014;134:1143-5.
    Pubmed KoreaMed CrossRef
  3. van Zuuren EJ. Rosacea. N Engl J Med 2017;377:1754-64.
    Pubmed CrossRef
  4. Kim MH, Byeon HS. Review for good platelet-rich plasma procedure in cosmetic dermatology and surgery. J Cosmet Med 2019;3:1-13.
  5. Masoudi E, Ribas J, Kaushik G, Leijten J, Khademhosseini A. Platelet-rich blood derivatives for stem cell-based tissue engineering and regeneration. Curr Stem Cell Rep 2016;2:33-42.
    Pubmed KoreaMed CrossRef
  6. Casabona F, Gambelli I, Casabona F, Santi P, Santori G, Baldelli I. Autologous platelet-rich plasma (PRP) in chronic penile lichen sclerosus: the impact on tissue repair and patient quality of life. Int Urol Nephrol 2017;49:573-80.
    Pubmed CrossRef
  7. Seifert B, Passweg JR, Heim D, Rovó A, Meyer-Monard S, Buechner S, et al. Complete remission of alopecia universalis after allogeneic hematopoietic stem cell transplantation. Blood 2005;105:426-7.
    Pubmed CrossRef
  8. Kang JS, Zheng Z, Choi MJ, Lee SH, Kim DY, Cho SB. The effect of CD34+ cell-containing autologous platelet-rich plasma injection on pattern hair loss: a preliminary study. J Eur Acad Dermatol Venereol 2014;28:72-9.
    Pubmed CrossRef
  9. Zhong W, Sumita Y, Ohba S, Kawasaki T, Nagai K, Ma G, et al. In vivo comparison of the bone regeneration capability of human bone marrow concentrates vs. platelet-rich plasma. PLoS One 2012;7:e40833.
    Pubmed KoreaMed CrossRef
  10. Pawlak-Buś K, Schmidt W, Olejarz M, Czyż A, Komarnicki M, Leszczyński P. Autologous hematopoietic stem cell transplant for progressive diffuse systemic sclerosis: procedural success and clinical outcome in 5-year follow-up. Reumatologia 2019;57:50-4.
    Pubmed KoreaMed CrossRef

This Article

Cited By Articles
  • CrossRef (0)

Author ORCID Information

Social Network Service